JP2020527569A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527569A5
JP2020527569A5 JP2020502226A JP2020502226A JP2020527569A5 JP 2020527569 A5 JP2020527569 A5 JP 2020527569A5 JP 2020502226 A JP2020502226 A JP 2020502226A JP 2020502226 A JP2020502226 A JP 2020502226A JP 2020527569 A5 JP2020527569 A5 JP 2020527569A5
Authority
JP
Japan
Prior art keywords
quercetin
therapeutic agent
subject
agent according
glucopyranosyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020502226A
Other languages
English (en)
Japanese (ja)
Other versions
JP7598137B2 (ja
JP2020527569A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042569 external-priority patent/WO2019018451A2/en
Publication of JP2020527569A publication Critical patent/JP2020527569A/ja
Publication of JP2020527569A5 publication Critical patent/JP2020527569A5/ja
Priority to JP2023061067A priority Critical patent/JP2023093533A/ja
Application granted granted Critical
Publication of JP7598137B2 publication Critical patent/JP7598137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020502226A 2017-07-17 2018-07-17 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法 Active JP7598137B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061067A JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533272P 2017-07-17 2017-07-17
US62/533,272 2017-07-17
PCT/US2018/042569 WO2019018451A2 (en) 2017-07-17 2018-07-17 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061067A Division JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020527569A JP2020527569A (ja) 2020-09-10
JP2020527569A5 true JP2020527569A5 (https=) 2021-08-26
JP7598137B2 JP7598137B2 (ja) 2024-12-11

Family

ID=65015329

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502226A Active JP7598137B2 (ja) 2017-07-17 2018-07-17 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法
JP2023061067A Pending JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061067A Pending JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Country Status (6)

Country Link
US (2) US11452709B2 (https=)
EP (1) EP3655015B1 (https=)
JP (2) JP7598137B2 (https=)
CN (1) CN111447940A (https=)
CA (1) CA3069701A1 (https=)
WO (1) WO2019018451A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069701A1 (en) 2017-07-17 2019-01-24 The Regents Of The University Of Colorado Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
CN112553286A (zh) * 2020-11-05 2021-03-26 北京大学深圳医院 自杀基因/前药系统疗效的评价方法和药物筛选方法
KR102817623B1 (ko) * 2021-05-14 2025-06-10 한국원자력의학원 방사선 치료 예후 예측용 또는 방사선 저항성 암 진단용 바이오마커 조성물
CN114392255A (zh) * 2021-11-10 2022-04-26 甘肃中医药大学 乌拉尔醇的新应用
CN114150054B (zh) * 2021-12-03 2022-08-02 中国科学院近代物理研究所 检测或评估电离辐射损伤或暴露的试剂及其所用tRNA衍生片段
CN114350787B (zh) * 2022-01-12 2023-06-30 中国人民解放军军事科学院军事医学研究院 一种ATE1的RNA m6A修饰作为γ射线辐射标志物的应用
CN119185555B (zh) * 2024-11-27 2025-04-04 浙江大学 一种用于干预捻转血矛线虫群体性别比例的siRNA及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5723750A (en) 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008106463A1 (en) 2007-02-26 2008-09-04 The Board Of Trustees Of The Univerity Of Illinois Phenylalanine for plant protection against uv radiation
WO2009100225A1 (en) * 2008-02-07 2009-08-13 Virobay, Inc. Inhibitors of cathepsin b
IT1393841B1 (it) 2009-04-30 2012-05-11 Giuliani Spa Composizione farmaceutica o dermatologica o nutrizionale o cosmetica per combattere l'azione di immunosoppressione provocata sulla pelle da agenti aggressivi
DE102010025970A1 (de) * 2010-07-02 2012-01-05 Papst Licensing Gmbh & Co. Kg Verfahren zur Bestimmung von Proteasen und ihren Proformen
CN101907614B (zh) * 2010-07-26 2012-05-23 中国科学院长春应用化学研究所 超高效液相色谱和质谱联用筛选组织蛋白酶b抑制剂的方法
CA3069701A1 (en) 2017-07-17 2019-01-24 The Regents Of The University Of Colorado Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy

Similar Documents

Publication Publication Date Title
JP2020527569A5 (https=)
JP2018126141A5 (https=)
JP6063628B2 (ja) 5−アザシチジンを用いる、非小細胞肺癌の治療方法
US20110250297A1 (en) Treatment of Hyperproliferative Disorders Using Cardiac Glycosides
US20100279978A1 (en) Methods of reducing the severity of mucositis
US20030236217A1 (en) Treatment of mucositis
US20200108089A1 (en) Gemcitabine Derivatives for Cancer Therapy
CN121512923A (zh) 核苷类药物的氨基磷酸酯衍生物的制剂
JP2010511039A5 (https=)
CN101402667B (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
CN107198777A (zh) 用于治疗癌症的含有聚核苷酸的药物组合物
RU2747467C1 (ru) Способ защиты от коронавирусной инфекции
Kaufman-Szymczyk et al. The effects of clofarabine in ALL inhibition through DNA methylation regulation
US20060165656A1 (en) Medicinal preparation having chemotherapeutic encapsulated therein
CN101653607B (zh) 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
CA2606727A1 (en) Lipid a analogs for treating oral and gastrointestinal mucositis
EP4469464A1 (en) Compositions and methods for covid-19 treatment
Pollak et al. Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction
Butranova et al. Spiramycin: The past and future of an antibiotic with pleiotropic effects in the therapy of community-acquired infections
Chu et al. Chemotherapy-induced recall dermatitis on a previously scalded wound in a patient with acute myeloid leukaemia
Kapse et al. A review on the 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease
AU2009230499B2 (en) Anti-tumor agent comprising cytidine derivative and carboplatin
IE20150193A1 (en) Kinetin (N6-Furfuryadenine) for preventing and treating mucositis and proctitis and erythemia
EP2415775B1 (en) Agent for inhibiting thickening of peritoneal membrane
CN120695191A (zh) Fr054在逆转胶质母细胞瘤替莫唑胺耐药中的应用